Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
Q3 revenue grew 26%, earnings and revenue beat estimates, and full-year revenue and margin guidance rose. Shares gained about 29% over 21 trading days and closed at the period high, though valuation and pullback risk remain.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ā¢ Robust Liquidity ā¢ Margin Compression ā¢ Strong Cashflow VCEL offers strong liquidity and cash flow, but margin pressure, negative retained earnings, high stock compensation, and an expensive valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ā¢ Short-term downtrend ā¢ Support holding ā¢ Resistance overhead Support Level: $39.60ā$39.72; stronger support $37.87 Resistance Level: $40.47ā$40.89; next $42.30ā$43.22 VCEL remains in a short-term downtrend over the last month, but holding above $39.60 and reclaiming $40.90 could support further recovery.
Sentiment & News
Key News Insights: ā¢ Institutional buying ā¢ MACI expansion ā¢ Capacity readiness Vericel's new institutional backing and MACI growth catalysts strengthen its outlook, though UK and ankle expansions remain pending.
AI Summary
VCEL has evolved into a cash-generative commercial biologics company, but at ~55x EBITDA its upside now depends on MACI sustaining strong adoption while margins recover; investors should favor evidence of operating leverage and treat any growth deceleration or continued margin compression as a valuation-reset risk.
Description
Vericel Corporation is a commercial-stage biopharmaceutical company that researches, manufactures and sells cellular therapies for sports medicine and severe burn care in the United States. Its marketed portfolio includes autologous cell-based treatments for knee cartilage defects and a permanent skin replacement for deep dermal and full-thickness burns, and it has a registration-stage biological for enzymatic eschar removal in severe thermal burns. The company was incorporated in 1989, previously known as Aastrom Biosciences, and is headquartered in Cambridge, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 6 | Nov 13 | VCEL | Vericel Corporation | Q3 revenue grew 26%, earnings and revenue beat estimates, and full-year revenue and margin guidance rose. Shares gained about 29% over 21 trading days and closed at the period high, though valuation and pullback risk remain. | Active | +0.0% |